Curevac’s COVID vaccine - Reuters News Agency

Curevac’s COVID vaccine

On June 16, Reuters was 17 seconds ahead when Curevac said its COVID vaccine was only 47% effective. When subsequent trial data released on June 30 confirmed this low efficacy, Reuters was minutes ahead of the competition with the news.

Market Impact

The news of the vaccine effectiveness on June 16 more than halved the value of Curevac shares. After the trial data release a few weeks later, the company’s shares sunk by another 10%.

Article Tags
Topics of Interest: Health
Type: Reuters News First
Sectors: Pharmaceuticals & Healthcare
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Major Global Story
FILE PHOTO: A dose of CureVac vaccine or a placebo is seen during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman/File Photo
Sign up for email updates
Sign up for email updates